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Background: To describe a rare manifestation of mantle cell lymphoma (MCL) in conjunctiva, with clinical,
hisologic, immunohistologic and genetic findings together with review of the Literature.
Case presentation: Most ocular adnexal lymphomas are extranodal marginal zone B-cell lymphomas of
mucosa-associated lymphoid tissue (MALT). A few cases of ocular adnexal mantle cell lymphomas have been
reported in the literature. We present a case of mantle cell lymphoma presenting as right conjunctival mass of at
least three months duration in a 64-year-old man. Histopathologic examination showed a proliferation of
monomorphous small-to-medium-sized lymphoid cells with cleaved nuclei in the subconjunctiva. By
immunohistochemistry, the infiltrate was positive for CD20, CD5, BCL-2, cyclin D1, and the transcription factor
SOX11. Fluorescent in situ hybridization demonstrated the presence of IGH-CCND1 fusion indicating t(11;14).
Conclusion: A rigorous approach to initial diagnosis and staging of small cell lymphomas of the ocular adnexa is
needed. The recognition of ocular MCL requires appropriate immunohistochemical staining and/or genetic
confirmation to differentiate this rare form of presentation of MCL from other more frequent small cell lymphomas.
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Ocular adnexal lymphomas (OALs) are the most com-
mon orbital neoplasms in adults, accounting for about
55% of all malignant orbital lesions [1,2]. About 80–90%
of primary ocular adnexal lymphomas are extranodal mar-
ginal zone B-cell lymphomas of mucosa-associated lymph-
oid tissue (MALT), which can arise within the intraconal
and extraconal orbital fat, lacrimal gland, extraocular mus-
cles, lacrimal sac, lids or conjunctiva [3]. Mantle cell lym-
phoma (MCL) is a relatively rare lymphoma, accounting
for less than 10% of all lymphomas. In the ocular adnexal
region, including rare cases of conjunctiva, MCL accounts
for between 1-5% [4] and 9% of the lymphomas [5]. The
orbit is the most commonly involved site of MCL invol-
vement, followed by the lacrimal gland and the eyelid,
similar to extranodal marginal zone lymphoma in this re-
gion [6]. Mantle cell lymphomas presenting in the ocular* Correspondence: y@daneshbod.com
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reproduction in any medium, provided the oradnexal region have a male predominance and are asso-
ciated with extraorbital extension at the time of diagnosis,
advanced stage disease, short median progression-free sur-
vival (PFS), and older-age at diagnosis [6,7]. In rare case
reports, a higher frequency of these tumors fail to co-
express CD5, rendering differential diagnosis between
conjunctival mantle cell lymphoma from extranodal mar-
ginal zone B-cell lymphomas of MALT more difficult [8].
We here report a case of MCL of the conjunctiva, as the
first clinical presentation of advanced-stage mantle cell
lymphoma, with extraocular lymph node and bone mar-
row involvement and review the literature in this field.
Case report
A 64-year-old man presented with a dark red palpable
mass in the bulbar conjunctiva (diameter: 0.5 cm) at the
medial canthus of the right eye. The mass was reported
to be present for at least three months (Figure 1). The
past medical history was uneventful and in particular no
B-symptoms were reported. CT scans of the right orbit
showed a limited bulbar conjunctival mass not involving
the lacrimal gland or orbital septum of the eyelids.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Right bulbar conjunctival mass, before treatment. Figure 3 Immunohistochemistry study for CD20 (,X20).
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infiltration by a monomorphic cell population composed
of small-to-medium-sized lymphocytes with irregular, in-
dented, or cleaved nuclei, 3/10 HPF mitotic rate and par-
tially nodular growth pattern, beneath the simple cuboidal
cell layer of surface conjunctival epithelium (Figure 2).
Immunohistochemical staining was performed on for-
malin-fixed, paraffin-embedded tissue sections, according
to the manufacturers’ protocols. The primary antibodies
used, the methods of antigen retrieval, and the dilution
rates were as follows: CD20 (L26) (Novocastra, Newcastle,
UK; microwave in 0.01 molar citrate buffer; 1:50), CD3
(PS1) (Novocastra, Newcastle, UK;microwave in 0.01
molar citrate buffer; 1:200), CD5 (4C7) (Novocastra,
Newcastle, UK; microwave in RE7113 solution; 1:100),
CD10 (56C6) (Novocastra, Newcastle, UK; microwave in
citrate buffer; 1:100), CD23 (1B12) (Novocastra, Newcastle,
UK; microwave in 0.01molar citrate buffer; 1:100), BCL-2
(3.1) (Novocastra, Newcastle, UK; microwave in citrateFigure 2 Histology of conjunctival mass biopsy showing
monomorphous infiltration of cleaved lymphoid cells (H&E X20).buffer; 1:100), cyclin D1 (P2D11F11) (Novocastra, Newcas-
tle, UK; Trypsin digestion; 1:50), Ki-67 (MM1) (Novocas-
tra, Newcastle, UK; microwave in citrate buffer; 1:100) and
SOX11 (Atlas Antibodies, Stockholm, Sweden; heat-
induced retrieval with ER2 BondMax buffer; 1:100) as pre-
viously described [9]. The tumor cells were positive for
CD20 (Figure 3), CD5, BCL-2, cyclin D1 (Figure 4),
and SOX-11 (Figure 4 inset) and negative for CD3, CD10,
and CD23. The Ki-67 proliferation index was 12%. By
fluorescence in situ hybridization (FISH) analysis on for-
malin-fixed, paraffin-embedded tissue sections using com-
mercially available LSI IGH/CCND1 XT dual color, dual
fusion and LSI CCND1 BAP break apart probes (Abbott-
Vysis), juxtaposition of IGH and CCND1 and a breakpoint
in the CCND1 locus were detected in 85% and 97% of nu-
clei, respectively, indicating presence of the MCL hallmark
translocation t(11;14)(q13;q32) (Figure 5). The histopatho-
logic and genetic findings confirmed the diagnosis of con-
junctival mantle cell lymphoma.Figure 4 Immunohistochemistry study for Cyclin D1 (,X20), and
(inset) Sox11 (,X20).
Figure 5 FISH using the LSI IGH/CCND1 probe showing
juxtaposition of IGH (green) and CCND1 (red) signals in the
majority of cells indicating IGH-CCND1 rearrangement
associated with t(11;14)(q13;q32).
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mology visit, however after two months was referred to
an oncologist. Extensive clinical staging was performed
and cervical lymph node and bone marrow involvements
were discovered. Gastroscopy and laboratory workups
such as liver function test, ESR, BUN, creatinine, β2 mi-
croglobulin, LDH, leukocyte count and serum protein
electrophoresis were in normal ranges. The patient was
allocated to the low-risk group with the MCL Inter-
national Prognostic Index. Combined chemotherapy with
Fludarabine, Cyclophosphamide and Rituximab (FCR) was
administered. After five cycles (approximately 5 months)
patient showed clinical response as a decrease in neck
lymph-node sizes and shrinkage of the conjunctival lesion
(Figure 6), however complete remission workup is pen-
ding after the sixth cycle.Figure 6 Right eye, 5 months after treatment.Consent
“Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.”
Discussion
Ocular adnexal lymphomas (OAL) account for 2% of all
non-Hodgkin lymphomas, and about 6-8% of extranodal
lymphomas [2]. The primary involvement of the conjunc-
tiva by lymphoma, comprises about one third of ocular
adnexal lymphoma, and 1.5% of all conjunctival tumors.
Like other primary ocular adnexal lymphomas, most of
the primary conjunctival lymphomas are low-grade extra-
nodal marginal zone B-cell lymphomas of MALT. Other
types of lymphomas such as diffuse large-cell lymphoma,
mantle cell lymphoma, and more aggressive histologic
subtypes are less commonly seen [10]. It seems that, MCL
in the ocular adnexal region is associated with poorer
prognosis compared with the much more common ex-
tranodal marginal zone lymphoma of mucosa-associated
lymphoid tissue type in the same region. Of the ocular ad-
nexal MCL, 80% present in stage III/IV. The median over-
all survival has been reported to be only 57 months [7].
According to the largest published series (n=21) of
ocular adnexal MCL including six cases with conjunc-
tival localization, patients with involvement of the orbital
and adnexal region as first presenting symptom (n=14)
had more frequently bilateral eye and bone marrow in-
volvement, and inferior OS as opposed to patients with
secondary ocular adnexal MCL (n=7) [5]. The majority
of patients in this series presented with stage IV disease
with nodal- and bone-marrow involvement, although all
patients were allocated in the low-risk group according
to the MCL International Prognostic Index score.
In multiple studies, patients with lymphoma of con-
junctival localization had a better outcome than lym-
phomas of other areas of the eye considering both local
and systemic relapse [11]. Only 31% patients with con-
junctival lymphoid tumors showed systemic lymphoma,
with fewer progressions than those involving other areas
of the orbit [1]. However, in recent studies conjunctival
lymphomas with nodal involvement have a worse prog-
nosis, and systemic disease is more common in patients
with lymphomas located at an extralimbal site (ie, in the
fornix or midbulbar region) [1,12]. A study analyzing
prognostic factors exclusively for low grade conjunctival
non-Hodgkin’s lymphoma identified four prognostic
factors for lower disease-free survival (DFS) and over-
all survival (OS) in the univariate analysis, namely age
greater than 59 years, nodal involvement, stage IV,
and an elevated IPI, but only the nodal involvement
maintained the negative impact on DFS in multivariate
analysis [12].
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several types of lymphomas including MZL or MCL.
Since the majority of patients with OALs initially present
to ophthalmologists, the current subdivision of OALs to
primary versus secondary adnexal lymphomas, based on
limited eye involvement (by imaging) and evidence of
disease dissemination or previous history of lymphoma,
is not practical, and the frequency of systemic dissemin-
ation at the time of diagnosis in patients who present
with initial ocular complaints is largely unknown [13]. In
line with this, our case although had initially presented
with occular lymphoma limited to conjunctiva, but due
to inadequate workup by ophthalmologist and loosing
follow up, subdividing our case to primary or secondary
was not possible. Our case expressed nuclear SOX11
and cyclin-D1, as most classical MCLs. SOX11 negative
MCLs are mainly leukemic and have a non-nodal pres-
entation. Although nodal dissemination in SOX11 nega-
tive patients may occur and they are usually associated
with TP53 mutation protein expression and more ag-
gressive behavior [14].
Conclusion
In conclusion, a rigorous approach to initial diagnosis
and staging of small cell lymphomas of the ocular ad-
nexa is needed. The recognition of ocular MCL requires
appropriate immunohistochemical staining and/or gene-
tic confirmation to differentiate this rare form of presen-
tation of MCL from other more frequent small cell
lymphomas. Also according to TNM staging of ocular
lymphomas, orbital imaging as well as systemic workup
is suggested for these rare ocular presentations.
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